PR Newswire·Jul 13, 2026, 4:01 PM ET

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio (Nasdaq: QTTB) commenced an underwritten public offering of $200 million in common stock & pre-funded warrants on July 13, 2026.
The company intends to grant underwriters a 30-day option to purchase an additional $30 million of common stock.
Morgan Stanley, Jefferies, & Cantor serve as joint book-running managers, with Oppenheimer & Co. as a book-running manager & H.C. Wainwright & Co. as lead manager.
Net proceeds will be used for working capital, including research, clinical development, & commercialization efforts for bempikibart.
The offering is conducted pursuant to an effective Form S-3 shelf registration statement filed June 25, 2026, & declared effective July 13, 2026.
Q32 Bio is advancing bempikibart (ADX-914), an anti-IL-7Rα antibody, in a Phase 2 program for alopecia areata.
Forward-looking statements regarding the offering size, timing, & use of proceeds are subject to risks & uncertainties outlined in the press release.